Developing a safe vaccine against group A streptococci [ 2014 - 2016 ]

Research Grant

Researchers: Prof Mark Walker (Principal investigator) ,  Dr Michael Batzloff ,  Dr Peter Moyle ,  Prof Istvan Toth ,  Prof Victor Nizet

Brief description Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified new protective candidate antigens, and we seek to undertake critical non-human primate studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Sanofi Pasteur) leading to human trials and the development of a safe group A streptococcal vaccine for human use.

Funding Amount $AUD 768,530.64

Funding Scheme Development Grants

Notes Development Grant